Azilsartan Medoxomil
Authoritative Clinical Reference
Navigation
DRUG NAME: Azilsartan Medoxomil
Therapeutic Class: Antihypertensive
Subclass: Angiotensin II Receptor Blocker (ARB)
Schedule (India): Schedule H
Route(s): Oral
Formulations Available in India:
• Tablets: 40 mg, 80 mg
ADULT INDICATIONS + DOSING
Primary Indications (Approved / Standard in India)
1. Hypertension
| Step | Dose | Notes |
| Starting dose | 40 mg once daily | Use 40 mg in most patients including those already on other antihypertensives; consider starting at 20 mg (half of 40 mg tablet) in volume-depleted patients or those on high-dose diuretics |
| Titration | Increase to 80 mg once daily after 2–4 weeks if blood pressure target is not achieved | |
| Usual maintenance dose | 40–80 mg once daily | |
| Maximum dose | 80 mg once daily | No additional benefit demonstrated beyond 80 mg |
• Azilsartan medoxomil is a prodrug; rapidly hydrolysed to the active moiety azilsartan during gastrointestinal absorption. Bioavailability of azilsartan is approximately 60%.
• Can be taken with or without food; absorption is not significantly affected by meals.
• Half-life of azilsartan is approximately 11 hours, supporting once-daily dosing.
• In head-to-head RCTs, azilsartan 80 mg demonstrated statistically greater 24-hour ambulatory blood pressure reduction compared to olmesartan 40 mg and valsartan 320 mg at their respective maximum approved doses (Bakris et al., Lancet 2011; White et al., Hypertension 2011). This may represent a clinical advantage in patients with uncontrolled hypertension on other ARBs.
• Can be used as monotherapy or in combination with other antihypertensives. In Indian practice, commonly combined with chlorthalidone or amlodipine for enhanced blood pressure control.
• First-dose hypotension risk is lower with ARBs than ACE inhibitors but remains relevant in salt/volume-depleted patients — correct volume status or reduce diuretic dose before initiation.
• Not currently listed on NLEM India 2022 (telmisartan 40 mg is the listed ARB). Azilsartan is a relatively newer ARB in the Indian market with limited long-term outcome trial data compared to telmisartan, losartan, or valsartan.
• Can be taken with or without food; absorption is not significantly affected by meals.
• Half-life of azilsartan is approximately 11 hours, supporting once-daily dosing.
• In head-to-head RCTs, azilsartan 80 mg demonstrated statistically greater 24-hour ambulatory blood pressure reduction compared to olmesartan 40 mg and valsartan 320 mg at their respective maximum approved doses (Bakris et al., Lancet 2011; White et al., Hypertension 2011). This may represent a clinical advantage in patients with uncontrolled hypertension on other ARBs.
• Can be used as monotherapy or in combination with other antihypertensives. In Indian practice, commonly combined with chlorthalidone or amlodipine for enhanced blood pressure control.
• First-dose hypotension risk is lower with ARBs than ACE inhibitors but remains relevant in salt/volume-depleted patients — correct volume status or reduce diuretic dose before initiation.
• Not currently listed on NLEM India 2022 (telmisartan 40 mg is the listed ARB). Azilsartan is a relatively newer ARB in the Indian market with limited long-term outcome trial data compared to telmisartan, losartan, or valsartan.
Secondary Indications — only Adults (Off-label, if any)
1. Proteinuric Chronic Kidney Disease / Diabetic Nephropathy — OFF-LABEL; Specialist only
• Dose: 40–80 mg once daily
• Duration: Long-term
• Specialist only: Co-management with nephrologist recommended when eGFR <30 mL/min/1.73 m²
• Evidence basis: No large-scale renal outcome trials exist specifically for azilsartan. Antiproteinuric effect is inferred from ARB class effect (RENAAL trial — losartan; IDNT — irbesartan). Small studies suggest azilsartan reduces proteinuria comparably to other ARBs. Indian nephrology specialist practice may use azilsartan when other ARBs are not tolerated or insufficient for blood pressure control. Telmisartan, losartan, or irbesartan are preferred ARBs for renoprotection due to stronger evidence base.
• Clinical notes: Monitor serum creatinine and potassium within 1–2 weeks of initiation. Accept up to 30% rise in creatinine from baseline; if greater, reduce dose or discontinue.
• Duration: Long-term
• Specialist only: Co-management with nephrologist recommended when eGFR <30 mL/min/1.73 m²
• Evidence basis: No large-scale renal outcome trials exist specifically for azilsartan. Antiproteinuric effect is inferred from ARB class effect (RENAAL trial — losartan; IDNT — irbesartan). Small studies suggest azilsartan reduces proteinuria comparably to other ARBs. Indian nephrology specialist practice may use azilsartan when other ARBs are not tolerated or insufficient for blood pressure control. Telmisartan, losartan, or irbesartan are preferred ARBs for renoprotection due to stronger evidence base.
• Clinical notes: Monitor serum creatinine and potassium within 1–2 weeks of initiation. Accept up to 30% rise in creatinine from baseline; if greater, reduce dose or discontinue.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
Not applicable. Safety and efficacy of azilsartan medoxomil have not been established in the paediatric population.
Secondary Indications — Paediatric doses (Off-label, if any)
Not applicable.
Clear statement: Not recommended below 18 years of age. No validated Indian or international paediatric dosing data exist for azilsartan. If an ARB is required in children, losartan is the preferred agent with established paediatric dosing data (IAP guidelines, CDSCO-approved paediatric labelling).
RENAL ADJUSTMENT
| Renal Status | Recommendation |
| Mild to moderate impairment (eGFR 30–89 mL/min/1.73 m²) | No dose adjustment required. Standard titration. |
| Severe impairment (eGFR <30 mL/min/1.73 m²) | Use with caution. Start at 40 mg once daily; titrate based on blood pressure response and renal function monitoring. Limited clinical experience in this population. |
| Haemodialysis | Azilsartan is highly protein-bound (~>99%) and is not expected to be significantly removed by haemodialysis. No supplemental dose required. Start at 40 mg once daily; limited data — specialist input recommended. |
| Peritoneal dialysis | NOT AVAILABLE in India — no specific dosing guidance exists. Use with caution under specialist supervision. |
• Azilsartan is primarily eliminated via hepatic metabolism (CYP2C9-mediated, minor pathway) and faecal excretion (~55%); renal excretion accounts for approximately 42% (mostly as inactive metabolites). Drug accumulation in renal impairment is not a major pharmacokinetic concern, but pharmacodynamic risks (hyperkalemia, worsening renal function) remain significant.
• Monitor serum creatinine and potassium within 1–2 weeks of initiation and after each dose change. Accept up to 30% rise in creatinine from baseline; if greater, reduce dose or discontinue.
• Monitor serum creatinine and potassium within 1–2 weeks of initiation and after each dose change. Accept up to 30% rise in creatinine from baseline; if greater, reduce dose or discontinue.
HEPATIC ADJUSTMENT
• Mild impairment (Child-Pugh A): No dose adjustment required. Standard initiation and titration.
• Moderate impairment (Child-Pugh B): Use with caution. AUC of azilsartan is increased approximately 1.6-fold in moderate hepatic impairment. Start at 40 mg once daily; generally well-tolerated, but monitor blood pressure and hepatic function closely. Titrate cautiously.
• Severe impairment (Child-Pugh C): Limited clinical experience. Avoid use or use only under specialist supervision. Significant increase in drug exposure is expected. Unlike telmisartan, azilsartan is not contraindicated in severe hepatic impairment per available labelling, but caution is strongly warranted.
• Moderate impairment (Child-Pugh B): Use with caution. AUC of azilsartan is increased approximately 1.6-fold in moderate hepatic impairment. Start at 40 mg once daily; generally well-tolerated, but monitor blood pressure and hepatic function closely. Titrate cautiously.
• Severe impairment (Child-Pugh C): Limited clinical experience. Avoid use or use only under specialist supervision. Significant increase in drug exposure is expected. Unlike telmisartan, azilsartan is not contraindicated in severe hepatic impairment per available labelling, but caution is strongly warranted.
CONTRAINDICATIONS
• Known hypersensitivity to azilsartan medoxomil, azilsartan, or any excipient in the formulation
• Pregnancy (second and third trimesters) — established fetotoxicity identical to other RAAS blockers (renal dysgenesis, oligohydramnios, skull ossification defects, neonatal renal failure, and death)
• Concurrent use with aliskiren in patients with diabetes mellitus or renal impairment (eGFR <60 mL/min/1.73 m²) — dual RAAS blockade increases risk of hypotension, hyperkalemia, and renal failure
• Bilateral renal artery stenosis or unilateral stenosis in a solitary functioning kidney — risk of acute renal failure
• Pregnancy (second and third trimesters) — established fetotoxicity identical to other RAAS blockers (renal dysgenesis, oligohydramnios, skull ossification defects, neonatal renal failure, and death)
• Concurrent use with aliskiren in patients with diabetes mellitus or renal impairment (eGFR <60 mL/min/1.73 m²) — dual RAAS blockade increases risk of hypotension, hyperkalemia, and renal failure
• Bilateral renal artery stenosis or unilateral stenosis in a solitary functioning kidney — risk of acute renal failure
CAUTIONS
• Volume-depleted or salt-depleted patients (e.g., on high-dose diuretics, vomiting, diarrhoea, restricted salt intake): Risk of symptomatic hypotension — correct volume status before initiation or start at the lowest available dose under observation
• Renal artery stenosis (unilateral with two functioning kidneys): Monitor renal function closely if ARB is considered essential; risk of reversible rise in creatinine
• Pre-existing renal impairment: Pharmacodynamic risk of hyperkalemia and worsening renal function
• Aortic stenosis, mitral stenosis, or hypertrophic obstructive cardiomyopathy: Increased risk of critical hypotension
• Patients on concomitant potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes: Risk of hyperkalemia
• Concurrent use with ACE inhibitors (dual RAAS blockade): Increased risk of hypotension, hyperkalemia, and renal impairment without additional cardiovascular benefit — avoid combination
• Primary hyperaldosteronism: ARBs are generally ineffective; specialist evaluation needed
• Patients with ischaemic heart disease or cerebrovascular disease: Excessive blood pressure reduction may precipitate ischaemic events
• Black patients: May have reduced antihypertensive response to ARB monotherapy; consider combination therapy
• Renal artery stenosis (unilateral with two functioning kidneys): Monitor renal function closely if ARB is considered essential; risk of reversible rise in creatinine
• Pre-existing renal impairment: Pharmacodynamic risk of hyperkalemia and worsening renal function
• Aortic stenosis, mitral stenosis, or hypertrophic obstructive cardiomyopathy: Increased risk of critical hypotension
• Patients on concomitant potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes: Risk of hyperkalemia
• Concurrent use with ACE inhibitors (dual RAAS blockade): Increased risk of hypotension, hyperkalemia, and renal impairment without additional cardiovascular benefit — avoid combination
• Primary hyperaldosteronism: ARBs are generally ineffective; specialist evaluation needed
• Patients with ischaemic heart disease or cerebrovascular disease: Excessive blood pressure reduction may precipitate ischaemic events
• Black patients: May have reduced antihypertensive response to ARB monotherapy; consider combination therapy
PREGNANCY
| Parameter | Detail |
| Overall safety statement | Contraindicated in second and third trimesters. Avoid in first trimester unless no suitable alternative exists. |
| Teratogenic risk | Second/third trimester exposure causes fetal renal failure, oligohydramnios, pulmonary hypoplasia, skull ossification defects, limb contractures, neonatal hypotension, and death — identical risk profile to all RAAS blockers (ACE inhibitors and ARBs). |
| First trimester | Limited data; discontinue as soon as pregnancy is confirmed and switch to a safe alternative. |
| Preferred alternatives | Labetalol (first-line), Methyldopa (first-line), Nifedipine extended-release (second-line) — as per Indian obstetric practice |
| Monitoring (if inadvertent exposure) | Serial ultrasound for fetal growth, amniotic fluid volume, and renal morphology; neonatal monitoring of renal function, blood pressure, and potassium after delivery |
LACTATION
| Parameter | Detail |
| Compatibility | NOT AVAILABLE in India — no human data on excretion of azilsartan in breast milk. Animal studies show azilsartan is present in milk. Not recommended during breastfeeding. |
| Preferred alternatives | Enalapril or captopril (ACE inhibitors with established lactation safety data). If an ARB is specifically required during lactation, no ARB has sufficient human lactation data — specialist decision required. |
| Expected drug levels in milk | Unknown (no human data) |
| Infant monitoring | If use is unavoidable, monitor infant for signs of hypotension (lethargy, poor feeding, excessive drowsiness), decreased urine output, and adequate weight gain |
ELDERLY
• Recommended starting dose: 40 mg once daily (no pharmacokinetic dose adjustment required; AUC is comparable in elderly and younger adults)
• Titration: Increase to 80 mg after 2–4 weeks if needed; may need slower titration in frail elderly
• Extra risks:
• Titration: Increase to 80 mg after 2–4 weeks if needed; may need slower titration in frail elderly
• Extra risks:
- Postural hypotension and resultant falls/fractures — particularly in patients on multiple antihypertensives or diuretics
- Age-related reduction in renal functional reserve — always check baseline eGFR and electrolytes; serum creatinine alone may underestimate renal impairment due to reduced muscle mass
- Greater susceptibility to hyperkalemia (reduced renal potassium excretion, polypharmacy)
- Assess for undiagnosed renovascular disease (atherosclerotic renal artery stenosis) before initiation in patients with diffuse atherosclerosis or refractory hypertension
• Monitor serum creatinine and potassium within 1–2 weeks of initiation and after each dose change
MAJOR DRUG INTERACTIONS
| Interacting Drug/Class | Effect | Mechanism / Notes |
| Potassium supplements, potassium-sparing diuretics (spironolactone, amiloride, eplerenone), potassium-containing salt substitutes | Severe hyperkalemia | ARBs reduce aldosterone-mediated renal potassium excretion. If combination is essential (e.g., spironolactone in resistant hypertension), monitor potassium within 1 week and frequently thereafter. |
| Lithium | Lithium toxicity (tremor, ataxia, confusion, renal impairment) | ARBs reduce renal lithium clearance. Monitor lithium levels closely; avoid combination if possible. |
| Aliskiren (in diabetics or CKD) | Hypotension, hyperkalemia, acute renal failure | Dual RAAS blockade. Contraindicated in patients with diabetes or eGFR <60 mL/min/1.73 m². |
| ACE inhibitors (dual RAAS blockade) | No additional cardiovascular benefit; increased renal adverse events, hyperkalemia, and hypotension | Avoid combining any ARB with any ACE inhibitor. |
| NSAIDs (including COX-2 inhibitors) — chronic use | Reduced antihypertensive effect; increased risk of acute kidney injury and hyperkalemia | NSAIDs reduce renal prostaglandin synthesis → decreased renal blood flow. The ”triple whammy“ combination (ARB + diuretic + NSAID) markedly increases AKI risk. Short-term NSAID use may be acceptable with monitoring. |
MODERATE DRUG INTERACTIONS
| Interacting Drug/Class | Effect | Notes |
| Diuretics (thiazides, loop diuretics) | Enhanced first-dose hypotension | Reduce or hold diuretic 2–3 days before azilsartan initiation, or start azilsartan at lowest dose under observation. Once stable, combination is therapeutically beneficial. |
| Antidiabetic agents (insulin, sulfonylureas, metformin) | Enhanced hypoglycaemic effect | ARBs may improve insulin sensitivity. Monitor blood glucose more frequently when initiating or titrating azilsartan in diabetic patients. |
| Cotrimoxazole (trimethoprim-sulfamethoxazole) | Hyperkalemia | Trimethoprim has potassium-sparing diuretic-like activity in the distal tubule. Monitor potassium, especially in elderly and those with renal impairment. |
| Corticosteroids, sympathomimetics | Diminished antihypertensive effect | Sodium and water retention by corticosteroids; sympathomimetics oppose vasodilatory action. |
| Warfarin | No clinically significant pharmacokinetic interaction | No dose adjustment required, but monitor INR when adding or stopping azilsartan as a standard precaution. |
| CYP2C9 inhibitors (fluconazole, amiodarone) | Potential modest increase in azilsartan levels | CYP2C9 is a minor metabolic pathway for azilsartan; clinical significance is limited but exercise caution with strong CYP2C9 inhibitors in hepatic impairment. |
COMMON ADVERSE EFFECTS
• Dizziness — related to blood pressure reduction, more common early in treatment or in volume-depleted patients
• Diarrhoea
• Fatigue
• Elevated serum creatinine — usually mild and reversible; reflects haemodynamic effect of RAAS blockade on glomerular filtration pressure rather than intrinsic renal toxicity
• Nausea
• Hypotension — particularly in volume-depleted patients
• Diarrhoea
• Fatigue
• Elevated serum creatinine — usually mild and reversible; reflects haemodynamic effect of RAAS blockade on glomerular filtration pressure rather than intrinsic renal toxicity
• Nausea
• Hypotension — particularly in volume-depleted patients
• Notably absent: dry cough. Unlike ACE inhibitors, ARBs do not inhibit bradykinin degradation and therefore carry negligible risk of cough. This is the principal reason for switching from ACE inhibitors to ARBs in clinical practice.
SERIOUS ADVERSE EFFECTS
• Angioedema: Rare with ARBs but reported. Requires immediate discontinuation and emergency management. Risk is lower than with ACE inhibitors but not zero. Exercise caution in patients with a history of ACE inhibitor-induced angioedema — cross-reactivity risk of approximately 2–17% reported across studies. Do not re-challenge if angioedema occurs with azilsartan.
• Hyperkalemia: Especially in renal impairment, diabetes, or concurrent potassium-elevating agents. Can cause life-threatening cardiac arrhythmias. Discontinue or reduce dose if potassium >5.5 mmol/L.
• Acute renal failure: Particularly in bilateral renal artery stenosis, severe heart failure, or volume depletion.
• Severe hypotension: May cause syncope, stroke, or myocardial ischaemia in susceptible patients (severe aortic stenosis, volume depletion, high-dose diuretics).
• Rhabdomyolysis: Very rare; reported in post-marketing surveillance for some ARBs as a class. Monitor for unexplained muscle pain, tenderness, or weakness with elevated creatine kinase levels.
• Hyperkalemia: Especially in renal impairment, diabetes, or concurrent potassium-elevating agents. Can cause life-threatening cardiac arrhythmias. Discontinue or reduce dose if potassium >5.5 mmol/L.
• Acute renal failure: Particularly in bilateral renal artery stenosis, severe heart failure, or volume depletion.
• Severe hypotension: May cause syncope, stroke, or myocardial ischaemia in susceptible patients (severe aortic stenosis, volume depletion, high-dose diuretics).
• Rhabdomyolysis: Very rare; reported in post-marketing surveillance for some ARBs as a class. Monitor for unexplained muscle pain, tenderness, or weakness with elevated creatine kinase levels.
MONITORING REQUIREMENTS
| Timing | Parameters |
| Baseline (before initiation) | Blood pressure; serum creatinine and eGFR; serum potassium and sodium; urinalysis (proteinuria if considering for renoprotection) |
| 1–2 weeks after initiation or each dose change | Blood pressure; serum creatinine and potassium. Accept up to 30% rise in creatinine from baseline. If rise exceeds 30% or potassium >5.5 mmol/L, reduce dose or discontinue. |
| Monthly for first 3 months | Blood pressure; renal function; potassium |
| Long-term (stable patients) | Blood pressure, serum creatinine, and potassium every 3–6 months |
| If used for proteinuric CKD (off-label) | Urine protein/creatinine ratio or albumin/creatinine ratio at baseline and every 3–6 months |
BRANDS AVAILABLE IN INDIA
• Azilday (Lupin)
• Zilarbi (Micro Labs)
• Zilarbi (Micro Labs)
FDCs available in India:
• Azilsartan medoxomil + Chlorthalidone: Available from select manufacturers
• Azilsartan medoxomil + Chlorthalidone: Available from select manufacturers
Note: Azilsartan medoxomil is a relatively newer ARB in the Indian market with limited brand availability compared to telmisartan, losartan, or olmesartan. Availability may vary by region and pharmacy; prescribers should verify local availability before initiating long-term therapy.
PRICE RANGE (INR)
• 40 mg tablet: ₹8–₹15 per tablet (approximate)
• 80 mg tablet: ₹12–₹22 per tablet (approximate)
• Not under NPPA price control (azilsartan is not on NLEM India 2022; telmisartan 40 mg is the listed ARB on NLEM)
• Government facility supply: Not commonly stocked; telmisartan and losartan are the preferred ARBs in public health facilities in India
• 80 mg tablet: ₹12–₹22 per tablet (approximate)
• Not under NPPA price control (azilsartan is not on NLEM India 2022; telmisartan 40 mg is the listed ARB on NLEM)
• Government facility supply: Not commonly stocked; telmisartan and losartan are the preferred ARBs in public health facilities in India
CLINICAL PEARLS
• Strongest blood pressure reduction among ARBs: In head-to-head RCTs, azilsartan 80 mg has shown statistically superior 24-hour ambulatory systolic blood pressure reduction compared to maximum doses of olmesartan (40 mg) and valsartan (320 mg). This may be clinically relevant when switching a patient with uncontrolled hypertension from another ARB — an option before adding additional antihypertensive agents.
• No long-term cardiovascular outcome data: Unlike telmisartan (ONTARGET/TRANSCEND), losartan (LIFE, RENAAL), and valsartan (Val-HeFT, VALUE), azilsartan does not have large-scale cardiovascular or renal outcome trials. Its clinical use is currently supported by blood pressure reduction data only. For patients requiring ARB therapy for cardiovascular risk reduction, heart failure, or renoprotection, other ARBs with proven outcome data should be preferred.
• Not on NLEM India: Azilsartan is not on the NLEM 2022 and is not price-controlled. Telmisartan is the NLEM-listed ARB and remains the most cost-effective and widely available first-line ARB choice in Indian practice.
• ACE inhibitor cough — any ARB is acceptable: If switching from an ACE inhibitor due to persistent dry cough, any ARB can be used. Azilsartan offers no specific advantage over telmisartan or losartan for this purpose unless additional blood pressure reduction is desired.
• Prodrug pharmacology: Azilsartan medoxomil is a prodrug hydrolysed to azilsartan during absorption. Unlike telmisartan (which is not a prodrug), this feature is shared with candesartan cilexetil and olmesartan medoxomil. No clinical disadvantage results from the prodrug mechanism as conversion is rapid and nearly complete.
• Chlorthalidone combination — pharmacologically rational: FDC of azilsartan with chlorthalidone is available in India. Chlorthalidone (rather than hydrochlorothiazide) provides superior 24-hour blood pressure reduction and has outcome data supporting its use. This combination is a rational choice for patients requiring dual-agent therapy.
• No long-term cardiovascular outcome data: Unlike telmisartan (ONTARGET/TRANSCEND), losartan (LIFE, RENAAL), and valsartan (Val-HeFT, VALUE), azilsartan does not have large-scale cardiovascular or renal outcome trials. Its clinical use is currently supported by blood pressure reduction data only. For patients requiring ARB therapy for cardiovascular risk reduction, heart failure, or renoprotection, other ARBs with proven outcome data should be preferred.
• Not on NLEM India: Azilsartan is not on the NLEM 2022 and is not price-controlled. Telmisartan is the NLEM-listed ARB and remains the most cost-effective and widely available first-line ARB choice in Indian practice.
• ACE inhibitor cough — any ARB is acceptable: If switching from an ACE inhibitor due to persistent dry cough, any ARB can be used. Azilsartan offers no specific advantage over telmisartan or losartan for this purpose unless additional blood pressure reduction is desired.
• Prodrug pharmacology: Azilsartan medoxomil is a prodrug hydrolysed to azilsartan during absorption. Unlike telmisartan (which is not a prodrug), this feature is shared with candesartan cilexetil and olmesartan medoxomil. No clinical disadvantage results from the prodrug mechanism as conversion is rapid and nearly complete.
• Chlorthalidone combination — pharmacologically rational: FDC of azilsartan with chlorthalidone is available in India. Chlorthalidone (rather than hydrochlorothiazide) provides superior 24-hour blood pressure reduction and has outcome data supporting its use. This combination is a rational choice for patients requiring dual-agent therapy.
VERSION
RxIndia v0.1 — 01 Mar 2026
REFERENCES
• CDSCO product inserts (Azilsartan medoxomil)
• Indian Pharmacopoeia
• API Textbook of Medicine
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• Harrison’s Principles of Internal Medicine
• NLEM India 2022 (for cross-reference; azilsartan not listed)
• ICMR Guidelines (hypertension management)
• Bakris GL et al. Lancet 2011;377:312–20 (azilsartan vs olmesartan and placebo — primary blood pressure efficacy data)
• White WB et al. Hypertension 2011;57:413–20 (azilsartan vs valsartan — head-to-head blood pressure comparison)
• Indian Pharmacopoeia
• API Textbook of Medicine
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• Harrison’s Principles of Internal Medicine
• NLEM India 2022 (for cross-reference; azilsartan not listed)
• ICMR Guidelines (hypertension management)
• Bakris GL et al. Lancet 2011;377:312–20 (azilsartan vs olmesartan and placebo — primary blood pressure efficacy data)
• White WB et al. Hypertension 2011;57:413–20 (azilsartan vs valsartan — head-to-head blood pressure comparison)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.